NFKB1 and neuroblastoma: We thus performed a series of pharmacological (using small molecule inhibitors at non-toxic concentrations, Fig. S2) and genetic (siRNA) loss of function experiments in rTGF-β1-treated NB cells examining the effect of these two pathways on NF-κB activation.